Protein Expression Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Expression System (Prokaryotic, Mammalian Cell, Insect Cell, Yeast, Others), By Product (Reagents, Competent Cells, Expression Vectors, Services, Instruments), By End user (Pharmaceutical and Biotechnological Companies, Academic Research, Contract research organizations, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Protein Expression Market will grow from USD 3.90 Billion in 2024 to USD 6.83 Billion by 2030 at a 9.80% CAGR. Protein expression describes the complex biological mechanisms by which genetic instructions are converted into functional proteins within living cells, constituting an essential methodology for biological research, drug discovery, and biopharmaceutical manufacturing. The market's growth is primarily fueled by the increasing global demand for recombinant proteins for therapeutic applications, including the development of advanced vaccines and monoclonal antibodies. Furthermore, sustained expansion in proteomics research and the rising adoption of personalized medicine initiatives significantly contribute to market progression.

However, the global protein expression market faces a notable impediment due to the substantial costs associated with sophisticated expression systems and specialized reagents, which can limit widespread adoption across diverse research and industrial settings. According to PhRMA, in 2024, the U.S. Food and Drug Administration approved 59 novel treatments and vaccines, alongside seven novel cell and gene therapies, highlighting the ongoing industry commitment to protein-driven innovation. These regulatory achievements underscore the critical role of efficient protein expression technologies in advancing the biopharmaceutical pipeline.

Key Market Drivers

The global protein expression market is significantly influenced by the increasing demand for biologics and protein therapeutics, which directly drives the need for sophisticated protein production capabilities. Biologics, encompassing monoclonal antibodies, advanced vaccines, and gene therapies, offer highly specific and effective treatment options for a broad spectrum of complex diseases. The consistent expansion in the development and manufacturing of these therapeutics mandates efficient and scalable protein expression systems. According to DCAT Value Chain Insights, in 2024, the FDA's Center for Drug Evaluation and Research approved 16 biological therapeutics, representing 32% of new drug approvals, highlighting the sustained output from this critical sector. Concurrently, growing research and development investments across the pharmaceutical and biopharmaceutical industries significantly propel market expansion. These substantial investments are crucial for exploring novel drug targets, optimizing expression platforms, and accelerating new therapies through the various stages of clinical development. Organizations are allocating considerable financial resources to innovation, recognizing that continuous discovery directly underpins future product portfolios. According to BioSpace, in May 2025, global pharmaceutical R&D spending in 2024 reached nearly $288 billion, indicating a robust financial commitment to scientific endeavors highly reliant on advanced protein expression technologies. This dual influence from both product demand and investment underpins the sustained growth trajectory of the market.

The cumulative effect of these primary drivers is evident throughout the broader industry landscape. Robust financial performance among key players in the life science tools and services sector reflects the underlying demand for protein expression solutions and related research infrastructure. For example, according to Thermo Fisher Scientific's report, in January 2025, this major provider of scientific instruments and services reported its full-year 2024 revenue as $42.88 billion, illustrating the substantial economic activity supporting critical research and biopharmaceutical manufacturing processes.

Download Free Sample Report

Key Market Challenges

The substantial costs associated with advanced expression systems and specialized reagents present a significant impediment to the growth of the global protein expression market. The financial outlay required for procuring, maintaining, and operating these sophisticated technologies, along with the recurring expense of highly specific reagents, creates a notable barrier to entry. This directly constrains smaller research institutions, emerging biotechnology companies, and academic laboratories from fully leveraging protein expression capabilities due to budget limitations, thereby impeding wider adoption across diverse research and industrial settings.

Consequently, the high capital and operational expenditure can slow down the initiation of new research projects, delay the scaling up of production for biopharmaceuticals, and temper the overall pace of innovation within the sector. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2024, the research-based pharmaceutical industry invested an estimated €55 billion in research and development in Europe. These considerable investments underscore how the specific high costs of protein expression systems and reagents contribute to the overall economic burden, ultimately restricting market expansion by hindering broader access and utilization of these essential technologies.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning for Expression Optimization significantly influences the global protein expression market by offering enhanced efficiency and predictive capabilities. These advanced computational methods enable researchers to precisely predict optimal protein expression conditions and design more effective protein constructs, accelerating drug candidate identification. According to a November 2024 report by the Information Technology and Innovation Foundation, AI has the potential to transform drug development, potentially reducing timelines by approximately half. This technological shift facilitates faster cycles and improved success rates in producing complex proteins. For instance, a September 2024 news release from the University of Texas at Austin detailed their team receiving nearly $2.5 million in grant funding for applying AI in protein engineering research for vaccine development.

Growing Outsourcing to Contract Research and Manufacturing Organizations represents a crucial operational trend driving the global protein expression market. Pharmaceutical and biotechnology companies increasingly rely on CRMOs for specialized expertise, scalability, and cost-efficient production of recombinant proteins. This strategic shift enables innovator companies to focus on core competencies, leveraging external partners for manufacturing complexities. DCAT Value Chain Insights reported in April 2025 that CDMOs are increasing manufacturing capacity due to rising outsourcing demand. A notable example is Lonza's $1.2 billion acquisition of Genentech's large-scale biologics manufacturing facility in Vacaville, California, in March 2024, as reported by Lonza. This substantial investment highlights the industry's commitment to expanding specialized contract manufacturing capabilities.

Segmental Insights

The prokaryotic segment is emerging as the fastest-growing component within the global protein expression market. This rapid expansion is primarily driven by its inherent advantages, including cost-effectiveness, high expression yields, and ease of scalability for industrial-level protein production. Prokaryotic systems, particularly *Escherichia coli*, offer straightforward cultivation methods and rapid growth rates, enabling the efficient production of large quantities of recombinant proteins in a short timeframe. Furthermore, their compatibility with advanced genetic engineering tools facilitates the development of microbial hosts for diverse applications in research, biotechnology, and the growing biomanufacturing sectors.

Regional Insights

North America leads the global protein expression market primarily due to its highly developed biotechnology and pharmaceutical sectors, which drive substantial demand for protein expression technologies in drug development, biologics, and biosimilars. The region benefits from significant investments in research and development from both government and private entities, fostering innovations in protein expression systems. Furthermore, the presence of numerous prominent academic and research institutions, coupled with a high incidence of chronic diseases, fuels demand for protein-based therapeutics. The supportive regulatory environment, including approvals from bodies like the US Food and Drug Administration, further strengthens North America's dominant position.

Recent Developments

• In May 2025, Nuclera, a biotechnology company, and Cytiva, a global life sciences leader, announced a strategic collaboration. The partnership involved combining Nuclera's eProtein Discovery™ System with Cytiva's Biacore™ surface plasmon resonance (SPR) technology. This integration was intended to significantly improve the characterization, production, and purification of proteins, which are critical processes in drug research and development. This collaboration advances capabilities within the global protein expression market by offering more efficient and comprehensive tools for protein analysis and manufacturing.

• In March 2025, GreenLab and Shiru announced a collaboration focused on the commercialization and scaling of sustainable protein production. This partnership leveraged GreenLab's proprietary corn expression system to develop and produce proteins more sustainably. The joint effort marked a significant milestone toward creating environmentally responsible ingredients that can address global nutritional needs without excessive resource depletion. This collaboration is directly relevant to the global protein expression market by promoting the adoption of sustainable methods for large-scale protein synthesis.

• In October 2024, Celltheon commercially launched its OmniCHO™ Transient Expression Kit, which is based on CHO-K1 cells. This breakthrough technology was introduced with the aim of transforming preclinical drug development by facilitating the expression of a wide range of proteins. The kit demonstrated versatility in expressing both straightforward and challenging proteins, including complex fusion proteins, antigens, and bispecifics. This innovation provides a valuable tool within the global protein expression market, catering to diverse protein synthesis requirements for research and therapeutic discovery initiatives.

• In June 2024, Syngene International Ltd., a contract research, development, and manufacturing organization (CRDMO), launched a new protein production platform. This platform was designed to enhance the speed and efficiency of protein production, supporting preclinical and clinical development phases, and ultimately accelerating product launches. The technology utilized within this platform was based on a cell line and transposon technology licensed from ExcellGene. This development directly contributes to advancements in the global protein expression market by offering enhanced capabilities for biopharmaceutical manufacturing and reducing time to market for novel protein-based therapeutics.

Key Market Players

• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• New England BioLabs, Inc.
• Promega Corporation
• QIAGEN GmbH
• Takara Bio, Inc.
• Oxford Expression Technologies Ltd
• LGC Genomics Limited

Report Scope:

In this report, the Global Protein Expression Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Protein Expression Market, By Expression System:

o   Prokaryotic

o   Mammalian Cell

o   Insect Cell

o   Yeast

o   Others

• Protein Expression Market, By Product:

o   Reagents

o   Competent Cells

o   Expression Vectors

o   Services

o   Instruments

• Protein Expression Market, By End user:

o   Pharmaceutical and Biotechnological Companies

o   Academic Research

o   Contract research organizations

o   Others

• Protein Expression Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Protein Expression Market.

Available Customizations:

Global Protein Expression Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Protein Expression Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]